Navigation Links
Study shows short-term kidney failure in heart patients may not be as detrimental
Date:7/1/2010

CINCINNATINew research led by UC Health cardiologists shows that while short-term worsening kidney function is frequent among patients with heart failure, these patients also have better outcomes than those who have persistent kidney failure.

These findings, published in the July 2010 edition of the Journal of Cardiac Failure, could lead to more effective interventions and treatments for patients with heart failure that develop kidney problems or failure as well.

"Worsening renal function is a warning complication in patients with acute heart failure syndrome," says Andrew Burger, MD, UC Health cardiologist and co-investigator in the study. "Between 30 and 50 percent of patients hospitalized for acute heart failure have further worsening of renal function during hospitalization, but there is very little data available about the clinical implication of transient versus persistent worsening of renal function in this setting.

"This study is the first of its kind to look at this relationship to help physicians assess outcomes and possibly determine the most efficient way to treat heart patients who develop kidney failure at any degree."

Researchers studied 467 patients with acute heart failure syndrome and their creatinine measurements on days 2, 5, 14 and 30 of the study.

Creatinine is a product of creatine phosphate, or energy phosphate, in the muscle and brain. It is filtered out of the blood by the kidneys. If the filtering of the kidney is deficient, blood levels rise, and creatinine levels in blood and urine are used to calculate the kidney's function.

In this study, worsening renal function was defined as persistent when serum creatinine remained greater than 0.5 mg/dL (milligrams per deciliter) above baseline throughout to day 30 and transient when the elevated creatinine levels decreased to less than 0.5 mg/dL above baseline within the 30-day period.

"Worsening renal function occurred in 115 patients39 of those cases were considered transient," says Burger.

He adds that researchers saw death in 17.3 percent of patients without worsening renal function, 20.5 percent of patients with transient worsening dysfunction and 46.1 percent of patients with persistent renal dysfunction.

"The patients with no change in renal function and transient dysfunction have the same outcome, while patients with persistent renal dysfunction are more like to die," Burger says. "Chronic heart failure encompasses an important interaction between the heart and the kidneys, and renal dysfunction often accompanies heart failure.

"These findings give cardiologists some insight into the degree of renal dysfunction and its association with mortality in both stable and acute heart failure syndrome. Hopefully, these results will lead to further studies that may help in determining better interventions and outcomes for patients with acute heart failure."


'/>"/>

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. Casual Sex Doesnt Cause Emotional Damage: Study
2. Study Finds Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks
3. Screening for Spinal Muscular Atrophy Not Cost-Effective: Study
4. New study finds possible source of beta cell destruction that leads to Type 1 diabetes
5. New Study Demonstrates Novel Use of Metabolic Imaging to Locate Sperm in Infertile Men -- Non-Invasive Imaging Procedure May Replace Invasive Techniques such as Testicula
6. Risk of stroke lower for recent Ontario immigrants: study
7. Definitive study confirms chemo benefit in postmenopausal breast cancer
8. Experimental stem cell treatment arrests acute lung injury in mice, study shows
9. Violence is part of the job say nurses as study shows only 1 in 6 incidents are reported
10. Controversial Autism Study Retracted by Medical Journal
11. Study Reveals Impact Of Health Insurance On Hispanics' Attitudes Towards Healthcare Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , ... February 08, 2016 , ... ... will be speaking on how healthcare companies can use newly released government data ... health of a population and intervene and capture the value they create to ...
(Date:2/7/2016)... , ... February 07, 2016 , ... Women's Excellence staff, ... Wear Red Day. National Wear Red Day is the first Friday each February ... disease and stroke cause 1 in 3 deaths among women each year – more ...
(Date:2/6/2016)... (PRWEB) , ... February 06, 2016 , ... With the ... easily add warm color grades to their footage. A LUT is a Lookup Table ... color to the corresponding color indicated by the table. By manipulating each pixel, LUT's ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... availability of the company's lighter, sleeker next generation LYNX VR Indoor Trainer with ... , Improvements in design and manufacturing not only reduce the weight of the ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... the addition of micro-needling services in their Napa Valley office. The technique utilizes ... Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest laser ... the first of its kind in the area ... through advanced laser treatment. The physician-owned and operated ... Suncoast by storm with its revitalizing skin ... advanced multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, Inc. ... the previously announced underwritten secondary offering of 11,027,558 shares ... consisting of affiliates of Blackstone and Goldman Sachs.  The ... initial price of $96.45 per share. The selling stockholders ...  Neither Zimmer Biomet nor any of its directors, officers ...
Breaking Medicine Technology: